, which is indispensable in the GT development pathway. The topics developed in the 3rd event in Evry in June 2004 focused on the biotechnological issues of GT products (vectors, plasmids, cell lines, etc), when they have to be prepared at industrial scale in a pharmaceutical production environment, which is a mandatory step in the development process of GT (see Figure 2 in Gonin et al in this supplement). During the conference, 114 scientific communications (36 full lectures, 23 short communications and 55 posters) were presented and highlighted the biology, use and industrial development of the main gene vectors, with general and expert information on (i) retroviral vectors (RVV), lentiviral vectors (LVV), adenoviral vector (AdV) and parvovirus-based, nonviral and other viral (alphavirus and herpes-based) vector systems; (ii) some applications in gene transfer into the liver, muscle, central nervous system and hematopoietic stem cells; (iii) biotechnological issues of scaling up, that is, theory and praxis of purification, cell cultures techniques and devices for industrial production of RVV, AdV and adeno-associated vector (AAV) vectors, and quality control issues; (iv) regulatory and ethical issues of gene transfer and GT. In a special session/round table, (v) some vector production facilities and services that are currently available for the scientific community in Europe and USA were presented. During the practical course, 32 selected researchers acquired hands-on experience on advanced methods for: (i) the production of AAV (ie transient transfection of 293 cells or infection of insect cells with recombinant baculoviruses) and purification with simple and fast methods using new ion-exchange chromatographic devices; (ii) preparations of large batches of AdV purified with chromatographic procedures; (iii) production of LVV vectors at large scale with improved packaging cell lines; (iv) new strategies to purify RVV and LVV pseudotyped with vesicular stomatitis virus protein G protein; and (v) characterization of viral vectors for basic biosafety parameters (ie physical and functional titration and assessment of adventitious contaminants and replication-competent particle).
Therefore, researchers and other GT professionals attending this course were trained in the scientific, technological and regulatory issues concerning the evolutionary process of GT products towards new biopharmaceuticals. This could be achieved by integrating the competence of different professions: namely, the researchers, who sign the gene transfer prototypes and protocols, and perform animal experimentation to validate proofs of principle; the regulators, who define the legal frame governing the clinical use of GT products; the industrialists, who allow technology transfers from the research benches to the biotech production plants, in order to transform the prototypes into exploitable products; and the physicians, involved in the last steps that lead to the completion of a clinical trial. Indeed, many GT operators from industries and other professions participated in all past events (see Table 1 , bottom line), indicating that these workshops correspond to a real need of these nonacademic sectors. In the 3rd Conference and Course in Evry, 25 companies and SMEs participated as exhibitors, sponsors, lecturers, and attendees of the conference and/or attendees of the practical course (see list of industrial participants). The participation of professionals from industry, regulatory/ ethical organizations and patients' associations in the three events indicates that the courses, by providing the GT community with specific workshops and round-table discussions, greatly contributed to implement the dialogue between the different operators, which is necessary to allow the flux of information, technologies and materials. These aspects of the developmental process of GT are discussed in the article by Gonin et al in this
Gene Therapy (2005) 12, S1-S4supplement. Therefore, our training programme, which schedules a series of eight future events up to 2010 (see www.vecteurotrain.org), will provide a permanent forum for the major GT stakeholders to work together in identifying and addressing the issues related to the GT development. This will greatly help the process of standardization of GT products and the harmonization of the regulations in Europe.
The success of the Vecteurotrain project to date is monitored by the increase of the number of the participants in the 2nd and 3rd event since the 1st Eurolabcourse, as well as by the number of countries (from European Union (EU) and abroad) represented (see Table   1 ). The major factors of the success is: first, the novelty of the training content, where the classical concepts of cell biology are updated in the context of the postgenomic knowledge and by integrating multiple disciplines, from basic biology to the high-throughput technologies of the 'omics' approaches. Therefore, researchers are attracted by the interdisciplinary topics developed, and the courses allow them to update their knowledge in life science and increase their expertise in transforming the innovations of research into products exploitable to improve the quality of life. Second, the novelty of the training format, which combines a large conference (plenary lectures, short communications, poster sessions and round-table discussions) with a practical lab course, increases the quantity and quality of the scientific information delivered and allows the interaction between young and senior scientists of different disciplines, sectors and countries. Since 2002 this led to the start of new collaborative projects, owing to the expertise acquired by the 96 participants in the three practical courses, and of the possibility to interact with all the participants offered by the Conference and Practical Course. Interestingly, the Vecteurotrain Scientific Office has been asked by these researchers to supervise these projects. Indeed, many new centres, to which the participants belong to, joined so far consortia in European Commission (EC)-funded projects, and the motivation to participate in research networks and in various training initiatives (see www.vecteurotrain.org) greatly increased. Furthermore, the interaction between senior scientists and young researchers gave the occasion to find interesting career opportunities in terms of both employment and mobility. Indeed, the Vecteurotrain Scientific office will take care of the follow-up of the career of the scientists by creating ASCO (Advanced Scientific Career Orientation, see www.vecteurotrain.org/asco.htm) a centre of career orientation and training. ASCO will assist the researchers in mobility projects in both outgoing and reintegration phases, by informing and advising on host institutions, and assisting them in the preparation of fellowship/grant applications, or in the job entry examinations. The ASCO centre, which will be a direct achievement of the Vecteurotrain activities, will implement the human resources locally by increasing the mobility potential, and will multiply the partnerships at national and international levels. Therefore, the Vecteurotrain project is playing an important role in enhancing the potential of the European Research Area (ERA) by supporting the development of research and development (R&D), especially in the Eastern European and Associated Candidate Countries, by involving the latter in research consortia and in other networking initiatives. The higher number of participants from these countries in the last two events (compared to the first event in 2002, see Table 1) indicates that new dynamics are generated after the enlargement of EU to 25 members, and that the Eastern European country (EECs) and associated candidate country (ie at the time of writing, Bulgaria, Romania and Turkey) (ACCs) are becoming new areas with a high potential for scientific and technological development. In the future, Vecteurotrain will work in tight coordination with European GT organizations, such as the European Society of Gene Therapy (ESGT), and EC-funded R&D projects and networks, in developing a multidisciplinary integrated training project that will match the objectives of the next EC 7th Framework Programme (FP7). It will extend the scientific training content to other disciplines and approaches of the postgenomic area, will enlarge the target audience (eg pre-Master students and the large population of nonspecialists) and will extend the European dimension of training, for example, to EECs and ACCs, to help their integration into the ERA and, thus, burst their development as new attractive entities of scientific, technological and economic interest. The articles in this issue have been written by participants of the 3rd Conference and Course. They present most of the topics that were developed during this event. The editors carefully selected the topics of this issue in order to avoid an overlap or a repetition with the special issue of The Journal of Gene Medicine, which was edited in the context of the 1st Eurolabcourse on vectorology and GT (see above). This supplement will both disseminate the results of the event and stimulate discussion and exchanges in the GT community, and will increase the motivation of young researchers to invest themselves as European professionals.
